Quadrant Capital Group LLC Acquires 40 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Quadrant Capital Group LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating) by 9.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 447 shares of the company’s stock after buying an additional 40 shares during the period. Quadrant Capital Group LLC’s holdings in IDEXX Laboratories were worth $244,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Heartland Bank & Trust Co raised its stake in IDEXX Laboratories by 2.2% during the 4th quarter. Heartland Bank & Trust Co now owns 938 shares of the company’s stock valued at $618,000 after buying an additional 20 shares during the last quarter. First National Bank of Hutchinson increased its position in IDEXX Laboratories by 1.8% during the fourth quarter. First National Bank of Hutchinson now owns 1,121 shares of the company’s stock valued at $738,000 after acquiring an additional 20 shares during the last quarter. Mission Wealth Management LP lifted its holdings in IDEXX Laboratories by 1.7% in the fourth quarter. Mission Wealth Management LP now owns 1,463 shares of the company’s stock valued at $963,000 after acquiring an additional 24 shares during the period. Freestone Capital Holdings LLC boosted its position in IDEXX Laboratories by 3.7% in the fourth quarter. Freestone Capital Holdings LLC now owns 699 shares of the company’s stock worth $460,000 after purchasing an additional 25 shares during the last quarter. Finally, American National Bank grew its stake in shares of IDEXX Laboratories by 18.5% during the 1st quarter. American National Bank now owns 160 shares of the company’s stock valued at $88,000 after purchasing an additional 25 shares during the period. 84.92% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $407.78 on Friday. The company has a quick ratio of 0.81, a current ratio of 0.89 and a debt-to-equity ratio of 1.68. IDEXX Laboratories, Inc. has a 52 week low of $318.50 and a 52 week high of $698.90. The stock’s 50-day simple moving average is $368.91 and its 200-day simple moving average is $443.56. The company has a market capitalization of $33.95 billion, a price-to-earnings ratio of 52.62, a PEG ratio of 5.36 and a beta of 1.14.

IDEXX Laboratories (NASDAQ:IDXXGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.25 by $0.02. IDEXX Laboratories had a return on equity of 104.47% and a net margin of 20.07%. The company had revenue of $836.55 million for the quarter, compared to analysts’ expectations of $836.47 million. During the same period in the previous year, the firm earned $2.35 EPS. The firm’s revenue was up 7.6% compared to the same quarter last year. As a group, analysts expect that IDEXX Laboratories, Inc. will post 7.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on IDXX shares. Bank of America downgraded shares of IDEXX Laboratories from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $550.00 to $470.00 in a report on Thursday, May 5th. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $440.00 to $420.00 and set an “overweight” rating for the company in a research report on Tuesday, July 26th. Morgan Stanley decreased their target price on IDEXX Laboratories from $603.00 to $573.00 and set an “overweight” rating on the stock in a report on Thursday. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 25th. Finally, Barclays decreased their price objective on IDEXX Laboratories from $700.00 to $582.00 and set an “overweight” rating on the stock in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $519.38.

About IDEXX Laboratories

(Get Rating)

IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

Featured Articles

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.